# US 2022/0090019 A1 · Stromal stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0090019 A1
- Document ID: US20220090019A1
- Status: Published application
- Kind: A1
- Application number: 17/540,067
- Filed: 2021-12-01
- Published: 2022-03-24
- Earliest claimed: 2012-02-10
- Assignees: Orbsen Therapeutics Limited
- Applicants: Orbsen Therapeutics Limited
- Inventors: Stephen Joseph Elliman
- Web page: https://patentgrep.com/patent/US20220090019A1

## CPC

- C12N 5/0662: {Stem cells}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 35/407: Liver; Hepatocytes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0663: {Bone marrow mesenchymal stem cells (BM-MSC)}
- C12N 5/0669: {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663)}
- C12Q 1/37: involving peptidase or proteinase
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Stromal stem cells are prospectively isolated from human bone marrow then expanded into clonal populations and cultured and used, the isolation being on the basis of expression of a cell surface marker, wherein the cell surface marker binds an antibody and wherein said antibody cross reacts with a cell surface marker found on mouse stromal stem cells or rat stromal stem cells, and optionally also on a cell of at least one other mammalian species selected from mouse, rat, horse, rabbit and pig cells. Useful stromal stem cell populations are positive for SDC2.

## Claims

### Claim 1

A composition comprising: (i) a population of mammalian stromal stem cells, wherein 30% or more of the cells are positive for SDC2; and (ii) a cryopreservant, wherein the population of mammalian stromal stem cells exhibits 1000-fold or more colony forming units compared with native pre-sorted mononuclear cells.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the cryopreservant is dimethylsulfoxide.

### Claim 3 (depends on 1)

The composition of claim 1, further comprising human serum albumin, saline, hyaluronic acid, or collagen.

### Claim 4 (depends on 1)

The composition of claim 1, wherein 50% or more of the cells are positive for SDC2.

### Claim 5 (depends on 1)

The composition of claim 1, wherein 75% or more of the cells are positive for SDC2.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the cells are human cells.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the cells are negative for CD45.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the composition is suitable for injection.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the cells are derived from bone marrow.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the cells are derived from umbilical cord.

### Claim 11 (depends on 1)

The composition of claim 1, wherein the cells are derived from adipose tissue, skeletal muscle, endometrium, placenta, umbilical cord blood, or Wharton's jelly.

### Claim 12 (depends on 1)

The composition of claim 1, wherein the population of mammalian stromal stem cells exhibits 1500-fold or more colony forming units compared with native pre-sorted mononuclear cells.

### Claim 13 (depends on 1)

The composition of claim 1, wherein said native pre-sorted mononuclear cells are less than 1% SDC2+.
